Equities research analysts at Keefe, Bruyette & Woods hoisted their target price on shares of Validus Holdings, Ltd. (NYSE:VR), from $42.00 to $44.00 in a research note issued to investors on Wednesday. Keefe, Bruyette & Woods’ price objective would indicate a potential upside of 18.12% from the stock’s previous close. Validus Holdings, Ltd. (NYSE:VR), net profit margin is 21.40% and weekly performance is 4.23%. On last trading day company shares ended up $38.92. Analysts mean target price for the company is $42.25. Validus Holdings, Ltd. (NYSE:VR), distance from 50-day simple moving average (SMA50) is 5.22%.
Alkermes Plc (NASDAQ:ALKS), CFO James M. Frates sold 7,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $50.22, for a total value of $351,540.00. Following the transaction, the chief financial officer now directly owns 44,225 shares in the company, valued at approximately $2,220,980. Alkermes Plc (NASDAQ:ALKS), advanced 2.82% in last trading session and ended the day on $51.75. ALKS, Gross Margin is 69.30% and its return on assets is -0.40%. Alkermes Plc (NASDAQ:ALKS), quarterly performance is 14.42%.
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced that the Company’s common stock has been added to the Russell Global, Russell 3000(R) and Russell Microcap(R) Indexes. The inclusion is part of the annual reconstitution of the entire Russell family of indexes that took place on June 27, 2014, following the close of market. Bio-Path Holdings Inc (NASDAQ:BPTH), shares moved down 6.56% in last trading session and was closed at $2.85, while trading in range of $2.77 – 3.02. Bio-Path Holdings Inc (NASDAQ:BPTH), year to date (YTD) performance is -28.75%.
On Jun 7, 2014, Zacks Investment Research downgraded Petmed Express Inc (NASDAQ:PETS), to a Zacks Rank #4 (Sell). Petmed Express Inc (NASDAQ:PETS), posted a mixed fourth-quarter fiscal 2014 with earnings beating the Zacks Consensus Estimate but revenues missing the same. Earnings per share (ETF:EPS) of 23 cents in the quarter came in 2 cents ahead of the Zacks Consensus Estimate. On the other hand, net sales in the quarter dropped 4.9% year over year to $48.6 million and also missed the benchmark by 6.5%.
Petmed Express Inc (NASDAQ:PETS), ended the last trading day at $13.38. Company weekly volatility is calculated as 2.09% and price to cash ratio as 7.99. Petmed Express Inc (NASDAQ:PETS), showed a negative weekly performance of 1.53%.
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), weekly performance is 1.09%. On last trading day company shares ended up $3.72. Analysts mean target price for the company is $8.38. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), distance from 50-day simple moving average (SMA50) is -2.44%.